650 related articles for article (PubMed ID: 15217497)
1. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
[TBL] [Abstract][Full Text] [Related]
2. Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer.
Esteva FJ; Sahin AA; Rassidakis GZ; Yuan LX; Smith TL; Yang Y; Gilcrease MZ; Cristofanilli M; Nahta R; Pusztai L; Claret FX
Clin Cancer Res; 2003 Nov; 9(15):5652-9. PubMed ID: 14654548
[TBL] [Abstract][Full Text] [Related]
3. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
4. Cluster analysis of S100 gene expression and genes correlating to psoriasin (S100A7) expression at different stages of breast cancer development.
Carlsson H; Petersson S; Enerbäck C
Int J Oncol; 2005 Dec; 27(6):1473-81. PubMed ID: 16273201
[TBL] [Abstract][Full Text] [Related]
5. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
6. Psoriasin interacts with Jab1 and influences breast cancer progression.
Emberley ED; Niu Y; Leygue E; Tomes L; Gietz RD; Murphy LC; Watson PH
Cancer Res; 2003 Apr; 63(8):1954-61. PubMed ID: 12702588
[TBL] [Abstract][Full Text] [Related]
7. Psoriasin (S100A7) expression is associated with poor outcome in estrogen receptor-negative invasive breast cancer.
Emberley ED; Niu Y; Njue C; Kliewer EV; Murphy LC; Watson PH
Clin Cancer Res; 2003 Jul; 9(7):2627-31. PubMed ID: 12855640
[TBL] [Abstract][Full Text] [Related]
8. Jun activation domain-binding protein 1 expression in breast cancer inversely correlates with the cell cycle inhibitor p27(Kip1).
Kouvaraki MA; Rassidakis GZ; Tian L; Kumar R; Kittas C; Claret FX
Cancer Res; 2003 Jun; 63(11):2977-81. PubMed ID: 12782606
[TBL] [Abstract][Full Text] [Related]
9. Concordant loss of fragile gene expression early in breast cancer development.
Guler G; Uner A; Guler N; Han SY; Iliopoulos D; McCue P; Huebner K
Pathol Int; 2005 Aug; 55(8):471-8. PubMed ID: 15998374
[TBL] [Abstract][Full Text] [Related]
10. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
[TBL] [Abstract][Full Text] [Related]
11. Expression and amplification of cyclin D1 in primary breast carcinomas: relationship with histopathological types and clinico-pathological parameters.
Naidu R; Wahab NA; Yadav MM; Kutty MK
Oncol Rep; 2002; 9(2):409-16. PubMed ID: 11836618
[TBL] [Abstract][Full Text] [Related]
12. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
13. BNIP3 as a progression marker in primary human breast cancer; opposing functions in in situ versus invasive cancer.
Tan EY; Campo L; Han C; Turley H; Pezzella F; Gatter KC; Harris AL; Fox SB
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):467-74. PubMed ID: 17255267
[TBL] [Abstract][Full Text] [Related]
14. E2F-1: a proliferative marker of breast neoplasia.
Zhang SY; Liu SC; Al-Saleem LF; Holloran D; Babb J; Guo X; Klein-Szanto AJ
Cancer Epidemiol Biomarkers Prev; 2000 Apr; 9(4):395-401. PubMed ID: 10794484
[TBL] [Abstract][Full Text] [Related]
15. A putative role for psoriasin in breast tumor progression.
Krop I; März A; Carlsson H; Li X; Bloushtain-Qimron N; Hu M; Gelman R; Sabel MS; Schnitt S; Ramaswamy S; Kleer CG; Enerbäck C; Polyak K
Cancer Res; 2005 Dec; 65(24):11326-34. PubMed ID: 16357139
[TBL] [Abstract][Full Text] [Related]
16. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
17. Expression of the cell death genes BNip3 and NIX in ductal carcinoma in situ of the breast; correlation of BNip3 levels with necrosis and grade.
Sowter HM; Ferguson M; Pym C; Watson P; Fox SB; Han C; Harris AL
J Pathol; 2003 Dec; 201(4):573-80. PubMed ID: 14648660
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of insulin-like growth factor binding protein-3 in invasive breast cancers and ductal carcinoma in situ: implications for clinicopathology and patient outcome.
Vestey SB; Perks CM; Sen C; Calder CJ; Holly JM; Winters ZE
Breast Cancer Res; 2005; 7(1):R119-29. PubMed ID: 15642160
[TBL] [Abstract][Full Text] [Related]
19. The S100A7-c-Jun activation domain binding protein 1 pathway enhances prosurvival pathways in breast cancer.
Emberley ED; Niu Y; Curtis L; Troup S; Mandal SK; Myers JN; Gibson SB; Murphy LC; Watson PH
Cancer Res; 2005 Jul; 65(13):5696-702. PubMed ID: 15994944
[TBL] [Abstract][Full Text] [Related]
20. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
